The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction

European Heart Journal

Volumn 36, Issue 30, 2015, Pages 1974-1982

  Floras, John S ^a   Ponikowski, Piotr ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Baroreceptor reflex; Chemoreceptor reflex; Exercise; Heart failure; Human; Parasympathetic nervous system; Sleep apnoea; Sympathetic nervous system

Indexed keywords

ARTERIAL BARORECEPTOR REFLEX; AUTONOMIC NERVOUS SYSTEM FUNCTION; CARDIAC CHEMOSENSITIVE REFLEX; CARDIOPULMONARY MECHANOSENSITIVE REFLEX; CENTRAL CHEMORECEPTOR REFLEX; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; KIDNEY NERVE; PARASYMPATHETIC FUNCTION; PERIPHERAL CHEMORECEPTOR REFLEX; PHENOTYPE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROGNOSIS; PULMONARY STRETCH RECEPTOR REFLEX; REFLEX; RENAL AFFERENT NERVE; REVIEW; SKELETAL MUSCLE REFLEX; SLEEP; SYMPATHETIC FUNCTION; AUTONOMIC NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM DISEASE; CHEMORECEPTOR CELL; COMPLICATION; HEART RATE; HEART STROKE VOLUME; INNERVATION; KIDNEY; MECHANORECEPTOR; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY NERVE; SKELETAL MUSCLE; SLEEP WAKE DISORDERS;

BIOLOGICAL MARKER;

AFFERENT PATHWAYS; AUTONOMIC NERVOUS SYSTEM DISEASES; BAROREFLEX; BIOMARKERS; CENTRAL NERVOUS SYSTEM DISEASES; CHEMORECEPTOR CELLS; HEART FAILURE; HEART RATE; HUMANS; KIDNEY; MECHANORECEPTORS; MUSCLE, SKELETAL; PROGNOSIS; SLEEP WAKE DISORDERS; STROKE VOLUME;

EID: 84939642930     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv087     Document Type: Review

References (90)

1. Amorim DS, Dargie HJ, Heer K, Brown M, Jenner D, Olsen EG, Richardson P, Goodwin JF. Isthereautonomic impairment incongestive (dilated) cardiomyopathy? Lancet 1981;1:525-527.
2. Floras JS. Sympathetic nervous system activation inhuman heartfailure: clinical implications of an updated model. J Am Coll Card 2009;54:375-385.
3. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probsfield JL, Yusuf S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventriculardysfunction. SOLVD Investigators. Circ 1996;94:690-697.
4. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circ 1995;92:3206-3211.
5. Taskforce of the European Societyof Cardiology and the North American Societyof Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Circ 1996;93:1043-1065.
6. Ando S, Dajani HR, Floras JS. Frequency domain characteristics of muscle sympathetic nerve activity in heart failure and healthy humans. Am J Physiol 1997;273(1 Pt 2):R205-R212.
7. Esler M. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular disease: the transition from mechanisms to medical management. J Appl Physiol 2010;108:227-237.
8. Millar PJ, Murai H, Floras JS. Paradoxical muscle sympathetic reflex activation in human heart failure. Circ 2015;131:459-468.
9. Notarius CF, Floras JS. Limitations of the use of spectral analysisof heart rate variability for the estimation of cardiac sympathetic activity in heart failure. Europace 2001;3:29-38.
10. Notarius CF, Butler GC, Ando S, Pollard MJ, Senn BL, Floras JS. Dissociation between microneurographic and heart rate variabilityestimates of sympathetic tone in normal and heart failure subjects. Clin Sci 1999;96:557-565.
11. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 1971;285:877-883.
12. Fallavollita JA, Heavey BM, Luisi AJ, Michalek SM, Baldwa S, Mashtare TL Jr, Hutson AD, deKemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63: 141-149.
13. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J, ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Card 2010;55:2212-2221.
14. Benedict CR, Weiner DH, Johnson DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, Greenberg B, Quinones MA, Yusuf S. Comparative neurohormonal responses in patients with preserved and impaired left ventricular function. Results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. J Am Coll Cardiol 1993;22:146A-153A.
15. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon A. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-824.
16. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. JACC 1993;22:72A-84A.
17. Porter TR, Eckberg DL, Fritsch JM, Rea RF, Beightol LA, Schmedtje JF Jr, Mohanty PK. Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J Clin Invest 1990;85:1362-1371.
18. Rundqvist B, Elam M, Bergman-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circ 1997;95:169-175.
19. Notarius CF, Atchison DJ, Floras JS. Impact of heart failure and exercise capacity on sympathetic response to handgrip exercise. Am J Physiol 2001;280:H969-H976.
20. Bibevski S, Dunlap ME. Ganglionic mechanisms contribute to diminshed vagal control in heart failure. Circ 1999;99:2958-2963.
21. Ramchandra R, Hood SG, Denton DA, Woods RL, McKinley MJ, McAllen RM, May CN. Basis for the preferential activation of cardiac sympathetic nerve activity in heart failure. Proc Natl Acad Sci USA 2009;106:924-928.
22. Watson AM, Hood SG, Ramchandra R, McAllen RM, May CN. Increased cardiac sympathetic nerve activity in heart failure is not due to desentization of the arterial baroreflex. Am J Physiol 2007;293:H798-H804.
23. Ebert TJ, Morgan BJ, Barney JA, Denahan T, Smith JJ. Effects of aging on baroreflex regulation of sympathetic activity in humans. Am J Physiol 1992;263:H798-H803.
24. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998;31:68-72.
25. Ferguson DW, Berg WJ, Roach PJ, Oren RM, Mark AL. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol 1992;69:523-531.
26. Dibner-Dunlap ME, Smith ML, Kinugawa T, Thames MD. Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. J Am Coll Cardiol 1996;27:358-364.
27. Floras JS. Arterial baroreceptor and cardiopulmonary reflex control of sympathetic outflow in human heart failure. Ann NY Acad Sci 2001;940:500-513.
28. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 2006;48:1005-1011.
29. Wang W, Schultz HD, Ma R. Volume expansion potentiates cardiac sympathetic afferent reflex in dogs. Am J Physiol 2001;280:H576-H581.
30. Minisi AJ, Thames MD. Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin. Circ 1993;87:240-246.
31. Wang W, Zucker IH. Cardiac sympathetic afferent reflex in dogs with congestive heart failure. Am J Physiol 1996;271:R751-R756.
32. Wang HJ, Wang W, Cornish KG, Rozanski GJ, Zucker IH. Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure. Hypertension 2014;64:745-755.
33. Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. Cardiovasc Res 2006;70:434-445.
34. Tracey KJ. The inflammatory reflex. Nature 2002;420:853-859.
35. Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 2011;4:669-675.
36. Goso Y, Asanoi H, Ishise H, Kameyama T, Hirai T, Nozawa T, Takashima A, Umeno K. Respiratorymodulationofmusclesympatheticnerveactivityinpatientswith chronic heart failure. Circ 2001;104:418-423.
37. Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. Symptomsand quality of life in heart failure: the muscle hypothesis. Br Heart J 1994;72:S36-S39.
38. Piepoli M, Ponikowski P, Clark AL, Banasiak W, Capucci A, Coats AJ. A neural link to explain the 'muscle hypothesis' of exercise intolerance in chronic heart failure. Am Heart J 1999;137:1050-1056.
39. Ponikowski PP, Chua TP, Francis DP, Capucci A, Coats AJ, Piepoli MF. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circ 2001;104:2324-2330.
40. Notarius CF, Millar PJ, Murai H, Morris BL, Marzolini S, Oh P, Floras JS. Divergent muscle sympathetic responses to dynamic leg exercise in heart failure and agematched healthy subjects. J Physiol 2015;593:715-722.
41. Ponikowski PP, Chua TP, Anker SD, Francis DP, Doehner W, Banasiak W, Poole-Wilson PA, Piepoli MF, Coats AJ. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circ 2001;104:544-549.
42. Di Vanna A, Braga AM, Laterza MC, Ueno LM, Rondon MU, Barretto AC, Middlekauff HR, Negrao CE. Blunted muscle vasodilatation during chemoreceptor stimulation in patients with heart failure. Am J Physiol 2007;293:H846-H852.
43. Kara T, Narkiewicz K, Somers VK. Chemoreflexes - physiology and clinical implications. Acta Physiol Scand 2003;177:377-384.
44. Niewinski P, Engelman ZJ, Fudim M, Tubek S, Paleczny B, Jankowska EA, Banasiak W, Sobotka PA, Ponikowski P. Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure. J Card Fail 2013;19:408-415.
45. Ponikowski P, Chua TP, Piepoli M, Ondusova D, Webb-Peploe K, Harrington D, Anker SD, Volterrani M, Colombo R, Massuero G, Giordano A, Coats AJ. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circ 1997;96:2586-2594.
46. Giannoni A, Emdin M, Poletti R, Bramanti F, Prontera C, Piepoli M, Passino C. Clinical significanceofchemosensitivity inchronicheartfailure: influenceonneurohormonal derangement, Cheyne-Stokes respiration and arrhythmias. Clin Sci 2008;114:489-497.
47. Stickland MK, Miller JD, Smith CA, Dempsey JA. Carotid chemoreceptor modulation of regionalblood flowdistributionduring exercise inhealth andchronicheartfailure. Circ Res 2007;100:1371-1378.
48. Notarius CF, Atchison DJ, Rongen GA, Floras JS. Effect of adenosine receptor blockade with caffeine on sympathetic response to handgrip exercise in heart failure. Am J Physiol 2001;281:H1312-H1318.
49. Del Rio R, Marcus NJ, Schultz HD. Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardiorespiratory function. J Am Coll Cardiol 2013;62:2422-2430.
50. Niewinski P, Janczak D, Rucinski A, Jazwiec P, Sobotka PA, Engelman ZJ, Fudim M, Tubek S, Jankowska EA, Banasiak W, Hart EC, Paton JF, Ponikowski P. Carotid body removal for treatment of chronic systolic heart failure. Int J Cardiol 2013;168:2506-2509.
51. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010;298:R245-R253.
52. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75-197.
53. Oda Y, Joho S, Harada D, Hirai T, Asanoi H, Inoue H. Renal insufficiency coexisting with heart failure is related to elevated sympathetic nerve activity. Auton Neurosci 2010;155:104-108.
54. Lambert G, Kaye DM, Lefkovits J, Jennings G, Turner AG, Cox HS, Esler M. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Circ 1995;92:1813-1818.
55. Aggarwal A, Esler M, Lambert GW, Hastings J, Johnston L, Kaye DM. Norepinephrine turnover is increased in suprabulbar subcortical brain regions and is related to whole-body sympathetic activity in human heart failure. Circ 2002;105:1031-1033.
56. Abboud FM, Thames MD. Interaction of cardiovascular reflexes in circulatory control. In: Shepherd JT, Abboud FM (eds). Handbook of Physiology, Section 2: The Cardiovascular System; Volume III: Peripheral Circulation and Organ Blood Flow, Part 2. Bethesda: American Physiological Society; 1983. p.675-753.
57. Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension 2012;59:755-762.
58. Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 2008;51:727-733.
59. Haack KK, Gao L, Schiller AM, Curry PL, Pellegrino PR, Zucker IH. Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure. Hypertension 2013;61:723-729.
60. Zhu GQ, Gao L, Li Y, Patel KP, Zucker IH, Wang W. AT1 receptor mRNA antisense normalizes enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure. Am J Physiol 2004;287:H1828-H1835.
61. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res 2004;95:937-944.
62. Huang BS, Yuan B, Leenen FH. Chronic blockade of brain 'ouabain' prevents sympathetic hyper-reactivity and impairment of acute baroreflexresetting in rats with congestive heart failure. Can J Physiol Pharmacol 2000;78:45-53.
63. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol 2001;281:H2241-H2251.
64. Ramchandra R, Hood SG, Watson AM, Allen AM, May CN. Central angiotensin type1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure. Hypertension 2012;59:634-641.
65. Arzt M, Young T, Finn L, Skatrud JB, Ryan CM, Newton GE, Mak S, Parker JD, Floras JS, Bradley TD. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern Med 2006;166:1716-1722.
66. Yumino D, Wang H, Floras JS, Newton GE, Mak S, Ruttanaumpawan P, Parker JD, Bradley TD. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. J Cardiac Fail 2009;15:279-285.
67. Spaak J, Egri ZJ, Kubo T, Yu E, Ando S, Kaneko Y, Usui K, Bradley TD, Floras JS. Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea. Hypertension 2005;46:1327-1332.
68. Usui K, Bradley TD, Spaak J, Kubo T, Kaneko Y, Floras JS. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Card 2005;45:2008-2011.
69. Bitter T, Westerheide N, Prinz C, Hassain MS, Vogt J, Langer C, Horstkotte D, Oldenburg O. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J 2011;32:61-74.
70. Yumino D, Wang H, Floras JS, Newton GE, Mak S, Ruttanaumpawan P, Parker JD, Bradley TD. Relationship between sleep apnoea and mortality in patients with ischaemic heart failure. Heart 2009;95:819-824.
71. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circ 2012;126:1495-1510.
72. rd ed. Philadelphia: Harcourt; 2015.
73. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;15:361-362.
74. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure differential effects on sympathetic activity. Circ 2001;104:2194-2199.
75. Kubo T, Parker JD, Azevedo ER, Atchison DJ, Newton GE, Picton P, Floras JS. Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover. Eur J Heart Fail 2005;7:878-881.
76. Cohen-Solal A, Rouzet F, Berdeaux A, Le Guludec D, Abergel E, Syrota A, Merlet P. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med 2005;46:1796-1803.
77. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circ 1997;96:1173-1179.
78. Hikosaka M, Yuasa F, Mimura J, Kawamura A, Motohiro M, Iwasaki M, Sugiura T, Iwasaka T. Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure. Cardiovasc Pharmacol 2002;40:875-880.
79. Ruzicka M, Floras JS, McReynolds AG, Coletta E, Haddad H, Davies R, Lennen FHH. Do high doses of AT1-receptor blockers attenuate central sympathetic outflow in humans with chronic heart failure? Clin Sci 2013;124:589-595.
80. De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, Francolini G, Bertocchi F, Ferrari R, Rizzon P, Pitzalis MV. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 2003;146:E17.
81. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heartfailure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-667.
82. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-1089.
83. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failuresecondaryto coronaryartery disease. Am JCardiol1995;76:1259-1265.
84. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, Dunselman PH, Boomsma F, Haaksma J, Lie KI. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. J Am Coll Cardiol 1995;26:983-990.
85. Adamson PB, Kleckner KJ, VanHout WL, Srinivasan S, Abraham WT. Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure. Circ 2003;108:266-269.
86. Hall AB, Ziadi MC, Leech JA, Chen SY, Burwash IG, Renaud J, deKemp RA, Haddad H, Mielniczuk LM, Yoshinaga K, Guo A, Chen L, Walter O, Garrard L, DaSilva JN, Floras JS, Beanlands RS. Effects of short-term continuous positive airway pressure on myocardial sympathetic nerve function and energetics in patients with heart failure and obstructive sleep apnea: a randomized study. Circulation 2014;130:892-901.
87. Gao J, Zucker IH, Gao L. Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure. Am J Hypertens 2014;27:1248-1256.
88. Zucker IH, Xiao L, Haack KK. The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond) 2014;126:695-706.
89. Millar PJ, Floras JS. Statins and the autonomic nervous system. Clin Sci (Lond) 2014;126:401-415.
90. Floras JS. The 'unsympathetic' nervous system of heart failure. Circ 2002;105:1753-1755.